Ipca Laboratories Ltd vs Laurus Labs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Ipca Laboratories Ltd is ₹ 1531 as of 30 Apr 15:30 . The P/E Ratio of Ipca Laboratories Ltd changed from 21.2 on March 2021 to 51.6 on March 2025 . This represents a CAGR of 19.47% over 5 yearsThe P/E Ratio of Laurus Labs Ltd changed from 19.8 on March 2021 to 92.4 on March 2025 . This represents a CAGR of 36.08% over 5 years The Market Cap of Ipca Laboratories Ltd changed from ₹ 24137 crore on March 2021 to ₹ 38088 crore on March 2025 . This represents a CAGR of 9.55% over 5 yearsThe Market Cap of Laurus Labs Ltd changed from ₹ 19427 crore on March 2021 to ₹ 33099 crore on March 2025 . This represents a CAGR of 11.24% over 5 years The revenue of Ipca Laboratories Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 2430 crore. This represent the decline of -100% The revenue of Laurus Labs Ltd for the Mar '26 is ₹ 1823 crore as compare to the Dec '25 revenue of ₹ 1784 crore. This represent the growth of 2.2% The ebitda of Ipca Laboratories Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 571.19 crore. This represent the decline of -100% The ebitda of Laurus Labs Ltd for the Mar '26 is ₹ 523.91 crore as compare to the Dec '25 ebitda of ₹ 485.97 crore. This represent the growth of 7.81% The net profit of Ipca Laboratories Ltd changed from ₹ 198.98 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Laurus Labs Ltd changed from ₹ 12.21 crore to ₹ 281.91 crore over 8 quarters. This represents a CAGR of 380.50% The Dividend Payout of Ipca Laboratories Ltd changed from 8.9 % on March 2021 to 15.59 % on March 2025 . This represents a CAGR of 11.86% over 5 yearsThe Dividend Payout of Laurus Labs Ltd changed from 11.22 % on March 2021 to 17.01 % on March 2025 . This represents a CAGR of 8.68% over 5 years .

About Ipca Laboratories Ltd

Ipca Laboratories Limited (IPCA) was incorporated on 19 October, 1949 under the name of 'The Indian Pharmaceutical Combine Association Limited.' Ipca is a fully integrated, pharmaceutical company manufacturing and marketing over 350 formulations and 80 API's covering various therapeutic segments.
The products of the Company are now sold in over 100 countries across the globe.
The Company has 18 manufacturing units in India manufacturing API's and formulations for the world market. Ipca's APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA) with operations in over 100 countries.

About Laurus Labs Ltd

Laurus Labs Limited was originally incorporated as 'Laurus Labs Private Limited' on September 19, 2005 at Hyderabad, Andhra Pradesh, India as a private limited company.
The company was subsequently converted into a public limited company and its name was changed to Laurus Labs Limited on February 12, 2007.
Subsequently the name of the company was changed to Aptuit Laurus Limited consequent to the strategic partnership entered into by the company with Aptuit Singapore on July 19, 2007.
Thereafter the company was converted into a private limited company and its name was changed to Aptuit Laurus Private Limited on July 24, 2007.
Subsequently, company was converted into a public limited company and the name of the company was changed to Laurus Labs Limited on August 16, 2016. Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology.

FAQs for the comparison of Ipca Laboratories Ltd and Laurus Labs Ltd

Which company has a larger market capitalization, Ipca Laboratories Ltd or Laurus Labs Ltd?

Market cap of Ipca Laboratories Ltd is 38,847 Cr while Market cap of Laurus Labs Ltd is 59,335 Cr

What are the key factors driving the stock performance of Ipca Laboratories Ltd and Laurus Labs Ltd?

The stock performance of Ipca Laboratories Ltd and Laurus Labs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ipca Laboratories Ltd and Laurus Labs Ltd?

As of May 3, 2026, the Ipca Laboratories Ltd stock price is INR ₹1531.2. On the other hand, Laurus Labs Ltd stock price is INR ₹1099.1.

How do dividend payouts of Ipca Laboratories Ltd and Laurus Labs Ltd compare?

To compare the dividend payouts of Ipca Laboratories Ltd and Laurus Labs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.